Abivax plunges on stock market after safety concerns emerge on treatment
Biotech company Abivax crashes over 30% on Paris stock exchange following announcement of cancer observations during clinical trials of its flagship drug.
Published 15sem2 sources✓ ConfirmedMajorupdated 5sem
Lire en français
≈ 26s
The fact
The press conference was held late European time on June 2, 2026, triggering a sharp market reaction.
The stock, despite previously encouraging efficacy results, faces a massive correction due to identified safety risks.
2 sources — click a link to read an article on the topic: